Edition:
United Kingdom

Vitrolife AB (VITR.ST)

VITR.ST on Stockholm Stock Exchange

600.00SEK
21 Feb 2018
Change (% chg)

-7.00kr (-1.15%)
Prev Close
607.00kr
Open
607.50kr
Day's High
607.50kr
Day's Low
594.50kr
Volume
21,625
Avg. Vol
32,005
52-wk High
717.00kr
52-wk Low
415.50kr

Latest Key Developments (Source: Significant Developments)

Vitrolife buys licensing rights for embryo transfer technology
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Vitrolife AB ::VITROLIFE ACQUIRES LICENSING RIGHTS TO TECHNOLOGY FOR EMBRYO TRANSFER.SAYS ‍INTENDS TO COMMERCIALISE TECHNOLOGY BY MARKETING A UNIQUE EMBRYO TRANSFER CATHETER​.SAYS ‍INITIAL PURCHASE PRICE AMOUNTED TO USD 5 MILLION​.SAYS ‍ACQUISITION IS EXPECTED TO IMPACT EBITDA PER SHARE MARGINALLY NEGATIVELY DURING 2018-2020 AND POSITIVELY AS FROM 2021​.  Full Article

Vitrolife Q3 core profit rises, like-for-like sales grow 20 pct​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Vitrolife AB :Q3 ‍sales amounted to SEK 246 (210) million, corresponding to an increase of 17 percent in SEK​.Q3 ‍sales growth was 20 percent in local currency and consisted in its entirety of organic growth​.Q3 ‍operating income before depreciation and amortisation (EBITDA) amounted to SEK 98 (71) million, corresponding to a margin of 40 (34) percent​.Says looking ahead, the market outlook is essentially unchanged.  Full Article

Vitrolife Q2 core profit rises, market outlook unchanged
Friday, 15 Jul 2016 

Vitrolife AB : Q2 sales amounted to sek 208 (184) million . Q2 operating income before depreciation and amortisation (ebitda) amounted to sek 74 (62) million, corresponding to a margin of 35 (34) percent. .Says market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife says buys OCTAX and MTG
Wednesday, 1 Jun 2016 

Vitrolife Ab : Vitrolife acquiring octax and mtg, jointly holding a world-leading position in laser technology for IVF . Vitrolife AB (publ) has completed the acquisition of 100% of the shares in OCTAX Microscience GmbH "OCTAX" and MTG Medical Technology Vertriebs-GmbH "MTG" . The consolidated net sales for the companies in 2015 amounted to approximately EUR 8.5 million (6.9) . The purchase sum for both companies amounted to EUR 13.7 million . The acquisitions are expected to be accretive to earnings per share from 2016 and onwards Further company coverage: [VITR.ST].  Full Article

BRIEF-Vitrolife hikes dividend, Q4 EBITDA up yr/yr

* Q4 ‍SALES AMOUNTED TO SEK 271 (251) MILLION, CORRESPONDING TO AN INCREASE OF 8 PERCENT IN SEK​